ADMA BIOLOGICS, INC. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land
ADMA BIOLOGICS, INC. (ADMA) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land of $20.00 million as of 2017-12-31, per its 10-K filed 2019-03-13.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) › Business Combination, Recognized Asset Acquired, Asset › Business Combination, Recognized Asset Acquired, Asset, Noncurrent › Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLand · last filed 2019-03-13
- 2017-12-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land $20.00M.
- 2017-09-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land $20.00M.
- 2017-06-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land $20.00M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land |
|---|---|
| 2017-12-31 | $20.00M 10-K · filed 2019-03-13 |
| 2017-09-30 | $20.00M 10-Q · filed 2017-11-03 |
| 2017-06-30 | $20.00M 10-Q · filed 2017-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |